Rapid cycling (RC) bipolar disorder is defined as four or more affective episodes within one year. RC bipolar disorder constitutes one of the most difficult forms of the illness to treat effectively. According to several studies, RC bipolar patients have more severe symptoms than non-rapid cycling bipolar patients. Most studies indicate that only 10% to 20% of patients with bipolar disorders experience rapid cycling, but this is of great concern to psychiatrists because of its association with treatment refractoriness. Second generation antipsychotics are increasingly being used in the treatment of bipolar disorder. A first step in the management of rapid-cycling bipolar disorder is the thorough assessment of possible medications or environmental factors that may destabilize the disorder and contribute to the recurrence of episodes, increasing cycle frequency, or both. All currently approved antidepressant drugs pose some risk of mood destabilization, but the risk is highest for tricyclic antidepressants. Discontinuation of antidepressants should be the first step in the management of RC patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Neurological Soft Signs in Type I Bipolar Disorder and Bipolar Spectrum Patients and Their Unaffected First-Degree Relatives: A Cross-Sectional Study.
Health Sci Rep
January 2025
School of Medicine, Behavioral Science Research Center of Imam Hossein Hospital Shahid Beheshti University of Medical Sciences Tehran Iran.
Background And Aims: This study aimed to compare neurological soft signs (NSSs) in type 1 bipolar disorder (BD), bipolar spectrum (BS) patients, and their unaffected first-degree relatives.
Methods: This descriptive cross-sectional study involved participants referred to the Psychiatric Department of Imam Hossein Hospital. Five groups ( = 25): patients with type 1 BD, patients with BS, unaffected first-degree relatives of the two groups, and a control group were evaluated using the Neurological Evaluation Scale (NES).
Identifying genetic differences between bipolar disorder and major depression through multiple genome-wide association analyses.
Br J Psychiatry
January 2025
Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California Los Angeles, USA; Department of Human Genetics, University of California Los Angeles, USA; and Department of Computational Medicine, University of California Los Angeles, USA.
Background: Accurate diagnosis of bipolar disorder (BPD) is difficult in clinical practice, with an average delay between symptom onset and diagnosis of about 7 years. A depressive episode often precedes the first manic episode, making it difficult to distinguish BPD from unipolar major depressive disorder (MDD).
Aims: We use genome-wide association analyses (GWAS) to identify differential genetic factors and to develop predictors based on polygenic risk scores (PRS) that may aid early differential diagnosis.
Investigating resting-state functional connectivity changes within procedural memory network across neuropsychiatric disorders using fMRI.
BMC Med Imaging
January 2025
Department of Physiology, Faculty of Medicine, AJA University of Medical Science, Tehran, Iran.
Background: Cognitive networks impairments are common in neuropsychiatric disorders like Attention Deficit Hyperactivity Disorder (ADHD), bipolar disorder (BD), and schizophrenia (SZ). While previous research has focused on specific brain regions, the role of the procedural memory as a type of long-term memory to examine cognitive networks impairments in these disorders remains unclear. This study investigates alterations in resting-state functional connectivity (rs-FC) within the procedural memory network to explore brain function associated with cognitive networks in patients with these disorders.
View Article and Find Full Text PDFMetacognitive Training for Subjects with Bipolar Disorder: A Randomized Controlled Trial.
Psychother Psychosom
January 2025
Bipolar Disorder Research Program (PROMAN), Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.
Introduction: Impairments in social cognition in bipolar disorder (BD) have been extensively described in the last decade but few treatment strategies have been studied to address this issue. This study presents findings from a randomized controlled trial (RCT) investigating the efficacy of metacognitive training for bipolar disorder (MCT-BD) compared to Treatment as Usual (TAU) among individuals with BD in remission. The aim was to determine whether MCT-BD could improve social cognition and overall functioning in this population.
View Article and Find Full Text PDFClinical and Demographic Predictors of Early Clozapine Discontinuation Across Mood and Psychotic Disorders.
J Clin Psychopharmacol
January 2025
Department of Pharmacy, Mayo Clinic, Rochester, MN.
Background: Clozapine is effective for treatment-resistant schizophrenia and bipolar disorder but is often discontinued due to adverse effects. This study compared early clozapine discontinuation rates and reasons in patients with mood and psychotic disorders.
Methods: Data from all individuals with mood or psychotic disorders who initiated clozapine for the first time at the inpatient psychiatric unit of Mayo Clinic, Rochester, Minnesota, between 2014 and 2022 were retrospectively analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!